All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, What is the rationale behind the combination of glofitamab + polatuzumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?
Bosch begins by discussing the bispecific antibody glofitamab, and the targeted conjugated polatuzumab, highlighting that since they have different targets (CD20 and CD79b, respectively), they can be used together. He outlines a trial discussed at ASH 2021 that found promising toxicity and complete response rates from the combination.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 47 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox